Q fever treatment
Treat acute Q fever with doxycycline (adults: 100 mg PO twice daily for 14 days); treat chronic Q fever (endocarditis/endovascular or other focal infection) with doxycycline 100 mg PO BID plus hydroxychloroquine 200 mg PO TID for at least 18 months, targeting drug levels and with expert follow‑up 1.
- Rationale and outcomes
- Acute: Early doxycycline shortens illness, prevents complications, and likely reduces progression to chronic disease—minimizing morbidity, mortality, and QOL loss 1.
- Chronic: The most widely endorsed regimen is doxycycline + hydroxychloroquine; despite predominantly observational support and recent calls for RCTs, it remains the standard with the largest clinical experience and best chance to prevent relapse, surgery, and death in endocarditis/vascular infection 1, 2.
Algorithmic treatment pathway
Suspected or confirmed acute Q fever (nonpregnant adults)
- Start doxycycline 100 mg PO BID x 14 days immediately (do not wait for serology) 1.
- Supportive care; avoid dairy 2 hours around dosing to optimize absorption 1.
- Children:
- ≥8 years or any age with severe disease/high risk (hospitalized, valvulopathy, immunocompromise, >14 days illness): doxycycline 2.2 mg/kg/dose PO BID (max 100 mg/dose) for 14 days 1.
- <8 years with mild/uncomplicated disease: doxycycline 2.2 mg/kg/dose PO BID for 5 days; if still febrile after 5 days, switch to TMP‑SMX 4–20 mg/kg TMP component BID for 14 days (max 800 mg SMX/dose) 1.
- Pregnancy: TMP‑SMX 160/800 mg PO BID throughout pregnancy; involve obstetrics/ID; monitor titers postpartum 1.
- Do NOT give prophylaxis after exposure or treat asymptomatic infection unless at high risk for chronic disease 1.
Chronic (“persistent focalized”) Q fever
- Indications: endocarditis or endovascular infection; also other focal disease (e.g., osteoarticular, chronic hepatitis) with compatible serology/clinical picture 1.
- Regimen: doxycycline 100 mg PO BID + hydroxychloroquine 200 mg PO TID for ≥18 months (endocarditis/vascular); noncardiac focal disease: same combo, duration guided by serology/clinical response; consult ID 1.
- Therapeutic drug monitoring/targets: doxycycline ≥5 μg/mL; hydroxychloroquine 1.0 ± 0.2 μg/mL; take HCQ with food/milk; avoid in G6PD deficiency; perform baseline and regular retinal exams for toxicity 1.
- Postpartum treatment: if serologic profile consistent with chronic Q fever (>12 months after delivery with phase I IgG ≥1:1024), treat with doxycycline + hydroxychloroquine for 12 months 1.
- Evidence nuance: Recent review highlights absence of definitive RCTs and mixed retrospective data, but doxycycline + hydroxychloroquine still has the most accumulated clinical experience and guideline support; until stronger evidence, adhere to this regimen to minimize mortality and relapse 2.
Key pitfalls and how to avoid them
- Delaying doxycycline in acute disease while awaiting labs—start empirically to prevent severe complications and chronic progression 1.
- Using tetracyclines in pregnancy—contraindicated; use TMP‑SMX and coordinate obstetric monitoring 1.
- Undertreating chronic disease or stopping early—requires prolonged therapy and serologic/clinical monitoring; inadequate duration increases relapse and mortality 1.
- Not monitoring for HCQ toxicity—obtain baseline ophthalmologic exam and periodic retinal screening; check G6PD; monitor drug levels to hit targets 1.
- Children <8 years with risk factors given only short courses—high‑risk pediatric cases need the full 14‑day doxycycline course 1.
When evidence diverges
- Alternatives (macrolides, fluoroquinolones, rifampin, TMP‑SMX) appear in observational literature, but guideline‑preferred regimens above take precedence for outcomes that matter most (morbidity, mortality, QOL). If intolerance/toxicity to HCQ, discuss second‑line combinations with ID, acknowledging weaker evidence 1, 3, 2.